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Background-—Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with
adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital
admission, at discharge, and at 1 and 6 months after discharge in a predefined subset (n=5135) of patients with acute coronary
syndromes in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Methods and Results-—The associations between osteoprotegerin and the composite end point of cardiovascular death,
nonprocedural spontaneous myocardial infarction or stroke, and non–coronary artery bypass grafting major bleeding during 1 year
of follow-up were assessed by Cox proportional hazards models. Event rates of the composite end point per increasing quartile
groups at baseline were 5.2%, 7.5%, 9.2%, and 11.9%. A 50% increase in osteoprotegerin level was associated with a hazard ratio
(HR) of 1.31 (95% confidence interval [CI], 1.21–1.42) for the composite end point but was not significant in adjusted analysis (ie,
clinical characteristics and levels of C-reactive protein, troponin T, NT-proBNP [N-terminal pro-B-type natriuretic peptide], and
growth differentiation factor-15). The corresponding rates of non–coronary artery bypass grafting major bleeding were 2.4%, 2.2%,
3.8%, and 7.2%, with an unadjusted HR of 1.52 (95% CI, 1.36–1.69), and a fully adjusted HR of 1.26 (95% CI, 1.09–1.46). The
multivariable association between the osteoprotegerin concentrations and the primary end point after 1 month resulted in an HR
of 1.09 (95% CI, 0.89–1.33); for major bleeding after 1 month, the HR was 1.33 (95% CI, 0.91–1.96).
Conclusions-—In patients with acute coronary syndrome treated with dual antiplatelet therapy, osteoprotegerin was an
independent marker of major bleeding but not of ischemic cardiovascular events. Thus, high osteoprotegerin levels may be useful
in increasing awareness of increased bleeding risk in patients with acute coronary syndrome receiving antithrombotic therapy.
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O steoprotegerin, a member of the tumor necrosis factorreceptor superfamily, exerts pleiotropic effects on bone
metabolism, endocrine function, and vascular inflammation,1
at least partly through acting as a decoy receptor for the
receptor activator of nuclear factor-jB ligand.1 Osteoprote-
gerin may colocalize with von Willebrand factor (vWF) in
platelets and on endothelial cells and is rapidly released by
inflammatory stimuli.2–4 Furthermore, osteoprotegerin is
expressed within the failing myocardium in both experimental
and clinical heart failure,5 and osteoprotegerin expression has
been observed in thrombotic material obtained from the site
of plaque rupture during myocardial infarction (MI).6 Thus,
osteoprotegerin seems to be a multifaceted mediator with
relevance for vascular and atherosclerotic disorders, although
details of its pathways of actions are still sparsely under-
stood.2–4
Circulating biomarkers provide independent information on
risk for adverse outcomes on top of established demographic
and clinical variables in patients with acute coronary
syndromes (ACSs).7–11 In addition to the established natri-
uretic peptides and cardiac troponins, which have been
extensively evaluated and shown to be suitable biomarkers for
prognosis and/or risk stratification of ACS,12,13 the recently
characterized inflammatory marker, growth differentiation
factor-15 (GDF-15), may also provide additional clinically
useful prognostic information in ACS.14 Also, cystatin C, a
marker of kidney function, has recently gained increasing
relevance as an independent marker of mortality in ACS.15
Accordingly, we have recently shown that NT-proBNP
(N-terminal pro-B-type natriuretic peptide),9,10 high-sensitivity
troponin T (hs-TnT),9,10 GDF-15,8–10 and cystatin C7 display
independent associations with cardiovascular outcomes,
including cardiovascular death, in the PLATO (Platelet Inhibi-
tion and Patient Outcomes) trial. Therefore, they represent
important adjustment variables for evaluating the indepen-
dent contribution of new biomarkers to prognosis.
Elevated osteoprotegerin levels have similarly been asso-
ciated with all-cause mortality16,17 and cardiovascular out-
comes, like MI18 and heart failure,19 in patients with
established coronary artery disease or ACS. In addition to
the potential modulatory role of osteoprotegerin on hemosta-
sis through interactions with vWF, elevated circulating
osteoprotegerin concentrations have been associated with
increased risk of bleeding complications in patients with
polycythemia vera,4 a condition with increased risk of both
thrombotic and hemorrhagic complications. Nonetheless, the
clinical importance of osteoprotegerin as a risk factor of
bleeding complications has never been reported in patients
with ACS.8
The PLATO trial encompassed a broad ACS population and
proved ticagrelor to be superior to clopidogrel in reducing the
composite end point of cardiovascular mortality, MI, or stroke.
There was no difference in the overall rates of major bleeding,
but there was an increase in bleeding unrelated to coronary
artery bypass grafting (CABG).20,21 In the current PLATO trial
substudy, we evaluated osteoprotegerin levels on hospital
admission and during 6 months of follow-up after ACS,
together with important prognostic biomarkers, in relation to
the composite end point of cardiovascular death, sponta-
neous MI, and stroke as well as to major non–CABG-related
bleeding.20,21 Finally, we explored the changes over time in
osteoprotegerin concentrations from admission through
6 months of follow-up.
Methods
Design and Study Population
The randomized placebo-controlled PLATO trial included a
total of 18 624 patients with ACS.20,21 The data, analytic
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure. The patients presented with either
ST-segment–elevation (STE) ACS or non-STE ACS and were
randomized to either clopidogrel or ticagrelor treatment in
addition to optimal medical therapy, including aspirin, and
optional invasive therapy.20,21 The need for additional oral
anticoagulant therapy (ie, triple therapy) after inclusion was a
contraindication in the PLATO trial. Patients were recruited
between October 11, 2006 and July 17, 2008, and were
followed up for up to 12 months after ACS.
Venous blood samples were obtained from all patients at
randomization as part of the main study. In addition, there
was a predefined substudy with serial blood sampling
conducted at selected sites aiming to obtain samples from
4000 patients at hospital discharge and after 1 month and
from at least 3000 of these patients also at 6 months.20,21 All
patients at these selected sites were continuously invited to
Clinical Perspective
What Is New?
• In patients with acute coronary syndrome treated with dual
antiplatelet therapy, osteoprotegerin was an independent
marker of major bleeding after adjustment for clinical risk
factors and multiple biomarkers prognostic for both cardio-
vascular events and bleeding, but it was not a marker of
ischemic cardiovascular events.
What Are the Clinical Implications?
• High osteoprotegerin levels may be useful in increasing
awareness of increased bleeding risk in patients with acute
coronary syndrome receiving antithrombotic therapy.
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the substudy, and inclusion of new patients proceeded until it
was estimated that at least 3000 patients would be available
for blood sampling at 6 months. Patients with a blood sample
at baseline and at least 1 additional blood sample during
follow-up were eligible for inclusion in the current analyses.
The overall aims of the biomarker substudy program have
previously been published.20,21 The study adhered to the
Declaration of Helsinki, the research protocol was approved
by national and institutional regulatory and ethics commit-
tees, and written informed consent was obtained from the
patients.
End Point Definition and Follow-Up
The prespecified primary end point of the present substudy
was the composite of cardiovascular death (defined as any
cardiovascular cause of death, sudden death, or any death
with no clear attributable noncardiovascular cause), sponta-
neous MI (defined as non–procedure-related, nonfatal, MI type
122), or stroke within 1 year of follow-up.20 The components
of the composite end point were also evaluated separately.
The secondary end point was PLATO-defined non-CABG major
bleeding, defined as follows: bleeding that was fatal, bleeding
that was intracranial, bleeding that required ≥2 U of blood
transfusion, or bleeding with a decrease in hemoglobin of
>5 g/dL20 (but not if directly related to a CABG operation).20
All end points in the PLATO trial were centrally adjudicated by
an independent and blinded clinical events adjudication
committee (A.A. and S.K.J.), comprising cardiologists or
neurologists, to subclassify causes of death and to subdivide
types of MI, stroke, and bleeding events.20,22
Sampling and Laboratory Analysis
Baseline venous blood samples were obtained within
24 hours of admission, before the administration of study
medication. The venous blood was centrifuged, and the
plasma samples were locally frozen in aliquots and stored at
70°C in a central repository at Uppsala Biobank until
biochemical analyses were performed. Osteoprotegerin con-
centrations were determined by enzyme-linked immunoassay
(R&D Systems, Stillwater, MN), as previously described and
validated.23 Briefly, wells were coated overnight with mono-
clonal mouse anti-human osteoprotegerin antibody in sterile
PBS. The standard was recombinant osteoprotegerin. Subse-
quent steps included biotinylated polyclonal goat anti-human
osteoprotegerin, streptavidin horseradish peroxidase, and
tetramethylbenzidine as substrate (ThermoFisher Scientific,
By, MA). The mean recovery of 2 samples spiked with
different concentrations of recombinant osteoprotegerin was
93%. The intra-assay and interassay coefficients of variation of
osteoprotegerin in the present study were 2.6% and 6.0%,
respectively. The sensitivity, defined as the mean3 SDs of
the zero standard, was calculated to be 15 pg/mL.
Hs-TnT, NT-proBNP, and cystatin C were determined with
sandwich immunoassays on the Cobas Analytics e601
Immunoanalyzer (Roche Diagnostics, Mannheim, Germany).
White blood cell (WBC) count and high-sensitivity C-reactive
protein (hs-CRP) were analyzed at the UCR Laboratory
(Uppsala, Sweden), with a spectrophotometric analysis
(Architect; Abbott, IL). GDF-15 was measured with a precom-
mercial assay (Roche Diagnostics) using a monoclonal mouse
antibody for capture and a monoclonal mouse antibody
fragment for detection in a sandwich assay format. The
results of these analyses in relation to outcomes and effects
of study treatment have previously been reported.8–10
Statistical Analysis
Osteoprotegerin concentrations at all time points are pre-
sented as medians with interquartile ranges (IQRs). The
changes of osteoprotegerin concentration over time were
tested by Wilcoxon signed-rank test. Baseline characteristics
are presented by osteoprotegerin quartile groups. Categorical
baseline variables are presented as frequencies and percent-
ages and compared by quartile groups of osteoprotegerin
using v2 tests. Continuous baseline variables are presented as
medians and IQRs and compared by quartile groups of
osteoprotegerin using the Kruskal-Wallis test. Natural loga-
rithmic transformations were performed for biomarker levels
to obtain an approximate normal distribution. The relationship
between osteoprotegerin and baseline characteristics and
biomarkers was assessed by multivariable linear models. We
calculated geometric means using the antilogarithms of the
model-adjusted means (ie, predicted marginal means) and
subsequently compared geometric means between groups
(eg, men/women) using ratios.
Crude event rates at 1 year, by osteoprotegerin quartile
groups at baseline, were estimated, as were Kaplan-Meier
event rates. The functional form of the relationship between
osteoprotegerin and outcomes was explored using cumulative
sums of martingale residuals and restricted cubic splines.24
The associations of osteoprotegerin concentrations (logarithm
transformed), on admission, with the composite end point of
cardiovascular death, spontaneous MI, or stroke and the
secondary end points of cardiovascular death and bleeding
were assessed by multivariable Cox proportional hazards
models. The hazard was based on a 50% increase in
biomarker concentration. Six models, with incremental addi-
tion of covariates, were used. Model 1 included the random-
ized treatment (ticagrelor or clopidogrel). Model 2 added the
following clinical baseline risk factors: age, sex, body mass
index, diabetes mellitus, chronic kidney disease, hyperten-
sion, smoking status, type of ACS, and history of heart failure,
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MI, percutaneous coronary intervention, CABG, stroke, or
peripheral artery disease. Model 3 included all variables from
model 2 together with hs-CRP level and WBC count. Model 4
included all the previously mentioned covariates with the
addition of cystatin C, a marker of kidney dysfunction, which
is strongly associated with an adverse outcome in this
population.7 Model 5 included all previously mentioned
variables in addition to hs-TnT and NT-proBNP. Model 6
included all previously mentioned variables and GDF-15. For
end points where osteoprotegerin was significantly associated
in model 6, discrimination was assessed using the Harrell
C-index. The multivariable models with and without osteopro-
tegerin were compared in terms of global model fit using
likelihood ratio tests.
The effects of osteoprotegerin levels on outcomes in
relation to predefined subgroup factors (ie, randomized
treatment, ACS type, invasive/noninvasive in-hospital treat-
ment approach, diabetes mellitus, sex, and smoking) were
evaluated using Cox proportional hazards models. These
models included quartile-divided osteoprotegerin levels, the
respective subgroup factor, and the osteoprotegerin subgroup
factor interaction term as independent variables. The propor-
tional hazards assumption was assessed by visual inspection
of Schoenfeld residual plots. A 2-sided P<0.05 was consid-
ered to be statistically significant, and there were no
adjustments for multiple comparisons. All statistical analyses
were performed with SAS 9.4 (SAS Institute, Cary, NC).
Results
Osteoprotegerin at Baseline and in Relation to
Baseline Characteristics
Baseline osteoprotegerin concentrations were available in
5135 patients, with a median (IQR) of 2.65 (2.02–3.62) ng/
mL. The blood samples for osteoprotegerin analysis were
collected a median (IQR) of 15 (IQR, 8–21) hours after the
index event or a median (IQR) of 10 (3–17) hours after
admission.
The background characteristics for the entire study
population with biomarkers available at baseline (n=16 401)
have previously been reported.7 Baseline characteristics by
osteoprotegerin quartile groups are presented in Table 1 and
showed that higher osteoprotegerin levels were associated
with several demographic features and several biomarkers.
Multivariable linear regression identified increasing age,
female sex, STE ACS, increasing levels of hs-TnT, GDF-15,
hs-CRP, and WBC, and lower cystatin C as the most prominent
predictors of osteoprotegerin at baseline (Table 2). In con-
trast, the hs-TnT level was not associated with osteoprote-
gerin levels at 1 month. Age, female sex, GDF-15, and hs-CRP
were the strongest predictors of osteoprotegerin at 1 month.
Osteoprotegerin Concentrations During Follow-
Up
In patients with a baseline osteoprotegerin concentration and
at least 1 follow-up sample (N=4679), the median (IQR)
concentration was 2.65 (2.02–3.62) ng/mL at baseline.
Figure 1 shows osteoprotegerin levels during 6 months of
follow-up. No blood samples were obtained beyond 6 months
of follow-up. Osteoprotegerin decreased significantly at
hospital discharge (median [IQR], 2.33 [1.83–3.03] ng/mL;
P<0.0001 versus baseline; n=4563) and further at 1 month
(median [IQR], 2.24 [1.80–2.85] ng/mL; P<0.0001 versus
baseline; n=4237), with a similar level at 6 months (median
[IQR], 2.23 [1.81–2.80] ng/mL; P<0.0001 versus baseline;
n=3084). No effects of randomized treatment were seen on
osteoprotegerin levels at any time point (Table 3).
Osteoprotegerin and Cardiovascular Outcomes
During a predefined follow-up of 1 year (median, 9 months),
the primary end point was observed in 434 patients (8.5%;
193 cardiovascular fatalities, 241 spontaneous MIs, and 62
stroke events). Restricted cubic spline analysis revealed a
relatively linear association between high osteoprotegerin
levels at baseline and incidence of the primary end point
(Figure 2). Kaplan-Meier analysis (Figure 3A) revealed
increasing event rates for the composite end point by
quartiles of baseline osteoprotegerin: 5.2%, 7.5%, 9.2%, and
11.9% for quartiles 1 to 4, respectively. As shown in
Figure 4A, the unadjusted hazard ratio (HR) and 95% confi-
dence interval (CI), per 50% increase in baseline osteoprote-
gerin concentration, was 1.31 (1.21–1.42). The association
remained significant after adjustment for clinical characteris-
tics and biomarkers of inflammation (ie, hs-CRP and WBC
count). However, after full multivariable adjustment, including
the cardiac biomarkers and GDF-15, the HR (95% CI) was 0.98
(0.88–1.09). The HR for cardiovascular death alone was
strongly attenuated and not significant after the addition of
hs-CRP and WBC count. Admission osteoprotegerin levels
were not associated with risk of stroke, whereas the
association with spontaneous MI was not significant after
adjustment for clinical characteristics (Table 4).
Osteoprotegerin and Major Bleeding
During follow-up, 200 patients had at least 1 non–CABG-
related major bleeding event. Cubic spline analysis indicated
an increase in risk of non–CABG-related major bleeding from
the third quartile (>2.7 ng/mL) of osteoprotegerin at admis-
sion (Figure 2). As shown in the Kaplan-Meier graph (Fig-
ure 3B), a particularly high risk of bleeding was found among
patients in the top quartile group of osteoprotegerin
(>3.6 ng/mL), with an HR (95% CI) of 3.19 (2.12–4.79)
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(>3.6 ng/mL) (n=1284) P Value*
Age, y 56 (50–63) 62 (54–69) 65 (56–72) 67 (57–75) <0.0001
Female sex 273 (21.3) 361 (28.1) 429 (33.4) 474 (36.9) <0.0001
Weight, kg 82 (73–93) 81 (72–90) 80 (70–89) 78 (68–90) <0.0001
BMI, kg/m2 27.8 (25.3–30.8) 27.8 (25.3–30.9) 27.5 (24.8–30.4) 27.2 (24.7–30.5) 0.0005
Risk factors
Habitual smoker 503 (39.2) 500 (38.9) 448 (34.9) 440 (34.3) 0.0104
Hypertension 787 (61.3) 846 (65.9) 884 (68.8) 870 (67.8) 0.0003
Dyslipidemia 569 (44.3) 558 (43.5) 551 (42.9) 495 (38.6) 0.0148
Diabetes mellitus 204 (15.9) 255 (19.9) 318 (24.8) 364 (28.3) <0.0001
Medical history
Angina pectoris 623 (48.6) 603 (47.0) 618 (48.1) 546 (42.5) 0.0080
Myocardial infarction 250 (19.5) 263 (20.5) 259 (20.2) 231 (18.0) 0.3893
Congestive heart failure 45 (3.5) 63 (4.9) 81 (6.3) 107 (8.3) <0.0001
PCI 190 (14.8) 179 (13.9) 129 (10.0) 136 (10.6) 0.0002
CABG 51 (4.0) 68 (5.3) 71 (5.5) 66 (5.1) 0.2731
TIA 15 (1.2) 29 (2.3) 41 (3.2) 28 (2.2) 0.0066
Nonhemorrhagic stroke 34 (2.7) 35 (2.7) 57 (4.4) 49 (3.8) 0.0313
Peripheral arterial disease 69 (5.4) 84 (6.5) 101 (7.9) 92 (7.2) 0.0776
Chronic kidney disease 22 (1.7) 31 (2.4) 48 (3.7) 78 (6.1) <0.0001
ST-segment–elevation MI 517 (40.3) 571 (44.5) 598 (46.6) 666 (51.9) <0.0001
GRACE risk score 124.0 (109–139) 133.0 (117–149) 137.0 (120–154) 143.0 (126–162) <0.0001
In-hospital medication
Aspirin 1263 (98.4) 1266 (98.6) 1259 (98.1) 1264 (98.4) 0.7270
Unfractionated heparin 661 (51.5) 699 (54.4) 691 (53.8) 756 (58.9) 0.0021
LMWH 714 (55.7) 688 (53.6) 702 (54.7) 666 (51.9) 0.2539
Fondaparinux 16 (1.2) 24 (1.9) 21 (1.6) 12 (0.9) 0.1946
Bivalirudin 21 (1.6) 23 (1.8) 16 (1.2) 16 (1.2) 0.5656
Glycoprotein IIb/IIIa
inhibitor
325 (25.3) 329 (25.6) 343 (26.7) 368 (28.7) 0.2135
b Blockers 1129 (88.0) 1118 (87.1) 1112 (86.6) 1112 (86.6) 0.6884
ACE inhibition and/or ARB 1103 (86.0) 1092 (85.0) 1131 (88.1) 1136 (88.5) 0.0265
Cholesterol lowering
(statin)
1210 (94.3) 1193 (92.9) 1199 (93.4) 1209 (94.2) 0.4181
Biomarkers
Hs-TnT, ng/L 119.0 (30.2–353.0) 158.0 (40.2–478.0) 135.0 (33.2–505.0) 274.5 (60.7–963.0) <0.0001
NT-proBNP, pmol/L 260 (102–593) 402 (136–932) 458 (143–1269) 728 (200–2215) <0.0001
Cystatin, mg/L 0.77 (0.65–0.90) 0.81 (0.65–0.97) 0.84 (0.69–1.05) 0.87 (0.69–1.11) <0.0001
GDF-15 1214 (960.8–1601) 1447 (1126–1918) 1638 (1220–2263) 2026 (1465–2996) <0.0001
Hs-CRP, mg/L 2.6 (1.3–6.0) 3.2 (1.4–6.9) 3.9 (1.6–10.0) 5.1 (2.1–16.0) <0.0001
Data are given as median (quartile 1–quartile 3) or number (percentage). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CABG,
coronary artery bypass grafting; GDF-15, growth differentiation factor-15; GRACE, Global Registry of Acute Coronary Events; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-
sensitivity troponin T; LMWH, low-molecular-weight heparin; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; and
TIA, transient ischemic attack.
*P values from the v2 test (categorical variables) or the Kruskal-Wallis test (continuous variables).
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versus the lowest quartile. When analyzed as a continuous
variable (Figure 4B), there was a 1.52-fold (95% CI, 1.36–
1.69) higher risk of bleeding per 50% increase in baseline
osteoprotegerin, which also remained significant after full
multivariable adjustment: HR, 1.26 (95% CI, 1.09–1.46). When
added to the full multivariable model, osteoprotegerin
contributed to discrimination about non–CABG-related major
bleeding (C-index, 0.70 versus 0.71; P=0.0024 from the
likelihood ratio test).
There was also a significant association between osteo-
protegerin and non–procedure-related major bleeding in the
fully adjusted model (n=99; HR, 1.24 [95% CI, 1.02–1.50];
P=0.0325). There were no interactions between osteoprote-
gerin levels and outcomes by randomized treatment or by
other tested subgroups, including type of ACS (STE or non-
STE ACS), diabetes mellitus, age, or sex.
Osteoprotegerin Concentrations and Outcomes
at 1 Month
Osteoprotegerin levels at 1 month were associated with the
occurrence of the primary composite end point after
1 month (n=240), with an HR (95% CI) of 1.59 (1.38–
1.83). After adjusting for inflammatory markers, the
association between osteoprotegerin at 1 month and the
composite end point was not significant: HR (95% CI), 1.19
(0.98–1.66) (Figure 4A). The number of non–CABG-related
major bleeding events after 1 month was low (n=75).
Nonetheless, the randomized treatment-adjusted and fully
adjusted HRs (95% CIs) were 1.78 (1.38–2.28) and 1.33
(0.91–1.96), respectively, per 50% increase in osteoprote-
gerin at 1 month (n=47) (Figure 4B). The number of
nonprocedural major bleeding events after 1 month was
58. This limited further statistical analyses.
Discussion
In patients with ACS treated with dual antiplatelet treatment,
the osteoprotegerin concentration was independently associ-
ated with increased risk of bleeding after adjustment for
clinical risk factors and multiple biomarkers prognostic for
both cardiovascular events and bleeding. In contrast, although
there were independent associations between the osteopro-
tegerin level on admission and after 1 month and the primary
composite cardiovascular end point of cardiovascular death,
spontaneous MI, or stroke after adjustment for clinical
characteristics and biomarkers of inflammation, these were
not sustained after complete adjustment for biomarkers of
cardiac function and GDF-15.
This study, for the first time in patients with ACS, showed
that increasing levels of osteoprotegerin were associated with
Table 2. Strongest Predictors of Osteoprotegerin Levels at Baseline and 1 Month
Background Characteristic
Baseline 1 Month
N P Value N P Value
Ticagrelor 1509 0.999 (0.978–1.021) 0.9536
Age, 10-y increase 4406 1.096 (1.081–1.111) <0.0001 3035 1.102 (1.087–1.116) <0.0001
Female sex 1319 1.088 (1.059–1.117) <0.0001 894 1.072 (1.045–1.100) <0.0001
STE-ACS 2052 1.104 (1.075–1.134) <0.0001 1471 0.972 (0.948–0.996) 0.0236
Hs-TnT, 10% increase 4406 1.002 (1.001–1.002) <0.0001 3035 1.000 (0.998–1.002) 0.9237
GDF-15, 10% increase 4406 1.023 (1.020–1.026) <0.0001 3035 1.013 (1.010–1.016) <0.0001
Cystatin-C, 10% increase 4406 0.991 (0.987–0.995) <0.0001 3035 1.003 (0.999–1.008) 0.1612
Hs-CRP, 10% increase 4406 1.004 (1.003–1.005) <0.0001 3035 1.003 (1.002–1.004) <0.0001
WBC count, 10% increase 4406 1.011 (1.007–1.015) <0.0001 3035 1.007 (1.002–1.011) 0.0022
GDF-15 indicates growth differentiation factor-15; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; STE-ACS, ST-segment–elevation acute coronary syndrome;
and WBC, white blood cell.
Figure 1. Box plots of osteoprotegerin levels on hospital
admission and during follow-up.
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bleeding complications during antiplatelet treatment. The
magnitude of the association between osteoprotegerin at
admission and bleeding was only marginally affected by the
addition of any biomarker and significantly improved the
performance of the multivariable model, indicating that
the role of osteoprotegerin on bleeding outcomes may be
exerted via pathways not reflected by other biomarkers. The
final addition of novel biomarker GDF-15 was crucial because
this marker has a proven strong association with bleeding
outcomes.8 A low circulating level of the endothelial activation
marker vWF is a risk factor for bleeding.25 Osteoprotegerin
binds vWF with high affinity, and this complex is present
in vivo and may influence bleeding risk.2,3 In addition,
osteoprotegerin may bind vWF reductase, thrombospondin-
1, and in late stages of thrombus formation, this interaction
may promote proteolysis of vWF multimers and prevent
platelet aggregation.2 This may be beneficial in limiting further
plaque progression; however, it could also promote bleeding.
Finally, osteoprotegerin is a modulator of vascular calcifica-
tion and is correlated with coronary calcium scores in the
Table 3. Effect of Randomized Treatment on Mean Osteoprotegerin Levels at Discharge and at 1 and 6 Months After
Randomization
Visit Treatment n* Mean (SD) Geometric Mean† Ratio of Geometric Means (95% CI) P Value‡
Discharge Ticagrelor 2263 2.62 (1.24) 2.39 1.01 (0.99–1.02) 0.5958
Clopidogrel 2300 2.56 (1.15) 2.38
Month 1 Ticagrelor 2103 2.46 (0.98) 2.28 0.99 (0.97–1.01) 0.2507
Clopidogrel 2134 2.43 (0.91) 2.30
Month 6 Ticagrelor 1513 2.46 (0.94) 2.30 1.01 (0.99–1.04) 0.1730
Clopidogrel 1571 2.39 (0.91) 2.26
CI indicates confidence interval.
*n includes patients with osteoprotegerin samples available at both baseline and the respective visit.
†The geometric means are calculated using the antilogarithms of the model-adjusted means of the logarithm-transformed data.
‡P values from an ANCOVA model with the natural logarithm of osteoprotegerin as the outcome variable and logarithm baseline osteoprotegerin and randomized treatment (ticagrelor or
clopidogrel) as independent variables.
Figure 2. Restricted cubic splines for osteoprotegerin in all patients at baseline on the investigated
outcomes. CABG indicates coronary artery bypass grafting; CI, confidence interval; CV, cardiovascular; and
MI, myocardial infarction.
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general populations26 and in patients with coronary artery
disease.27 Because the degree of coronary calcification is a
risk factor for non–CABG-related major bleeding in ACS,28 it is
conceivable that the association between osteoprotegerin and
bleeding risk in our study could reflect effects of calcified
arteries on bleeding. Such interactions between osteoprote-
gerin, hemostasis, and calcification warrant further explo-
ration. The serial analyses of osteoprotegerin revealed a
decrease in median levels that stabilized at the 1-month
follow-up. The effect of osteoprotegerin on bleeding and the
univariate association with ischemic end points and mortality
all exhibited numerically greater point estimates at 1 month.
However, the number of events, especially bleeding events,
rapidly decreases after the first month of the follow-up, and
this is reflected by the large CIs at 1 month. Thus, although
the association with bleeding was not significant in the fully
adjusted model at 1 month, our data support that osteopro-
tegerin may be a novel and stable marker for major bleeding
in the setting of ACS and antithrombotic therapy. However,
we are unable to draw any conclusions on a possible
causative role of osteoprotegerin on ischemic events or
bleeding in patients with ACS receiving antithrombotic
therapy. Furthermore, it would also be of interest in
forthcoming studies to evaluate if osteoprotegerin could be
a bleeding biomarker in patients not taking dual antiplatelet
therapy or aspirin monotherapy.
Several biomarkers, on admission for ACS, provide
clinically important information on risk for cardiovascular
morbidity and mortality, including NT-proBNP (myocardial
dysfunction),9,10 cardiac troponins (myocardial necrosis),29
and cystatin C (kidney function).7,11 Circulating osteoprote-
gerin has been reported to be associated with cardiovascular
outcomes, including mortality, MI, and incident heart failure,
in several ACS cohorts.16–19 However, although most of
these studies include natriuretic peptides,16,17,19 tro-
ponins,16–18 and CRP16–18 in their adjustment strategy,
none include GDF-15, which increases in response to
myocardial stress associated with inflammation and tissue
damage30 and is becoming a recognized biomarker in
ACS.9,10,14 In this large study population, the association
between high osteoprotegerin levels at admission and risk of
the primary end point or cardiovascular death was markedly
attenuated and no longer significant after addition of NT-
proBNP, hs-TnT, and GDF-15 to the model that included
clinical variables and inflammatory biomarkers. This finding
suggested that osteoprotegerin in the short-term phase
could reflect a local or systemic inflammatory response to
myocardial necrosis, but could not independently predict
prognosis. Osteoprotegerin is strongly expressed within the
failing myocardium,5 correlates with infarct size after ACS,31
and was strongly associated with cardiac troponin levels in
the short-term phase in our study. Thus, a strong influence
of the short-term phase reaction could attenuate the
association with adverse ischemic events, as is seen for
CRP.32 At 1 month, hs-CRP and, in particular, GDF-15 were
among the strongest predictors of osteoprotegerin; they are
more closely related to adverse cardiovascular outcomes in
our cohort and could, therefore, partly explain the lack of
association with outcomes, compared with other studies that
lack GDF-15 measurements. Differences compared with our
previous report in 897 patients with ACS, in whom an
association between high osteoprotegerin levels at admis-
sion and all-cause mortality was observed, could also be
attributable to the markedly longer follow-up time
(89 months) and, thus, a larger proportion and incidence
of fatalities.17 Nonetheless, similar to the present study, the
Figure 3. Kaplan-Meier estimated event rates of the primary outcome (composite of cardiovascular death, spontaneous myocardial
infarction [MI], and stroke; A) and non–coronary artery bypass grafting (CABG)-related major bleeding (B) by quartiles of osteoprotegerin. OPG
indicates osteoprotegerin.
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relationship between osteoprotegerin and MI was not
significant in adjusted analysis.17 Also, in a study by
Roysland et al, who evaluated osteoprotegerin in 4463
patients with non-STE ACS with a similar follow-up as our
study,16 the association with MI was not present in adjusted
analysis, although an association with cardiovascular death
persisted in adjusted analysis.
Limitations
The current study provides insights to the role of osteopro-
tegerin in a population with ACS, but it has some limitations.
The PLATO trial comprises a broad population with ACS.
However, patients requiring dialysis or with recent significant
bleeding were not eligible. Furthermore, because mortality
Figure 4. Forest plot of hazard ratios (HRs) and 95% confidence intervals (CIs) per 50% increase in osteoprotegerin concentration on the
primary composite end point (A) and the secondary end point of non–coronary artery bypass grafting (CABG) major bleeding (B) during up to
1 year of follow-up. HRs are presented per 50% increase in biomarker level and are presented after incremental addition of covariates, as
detailed left of A and in Statistical Analysis. Point estimates in blue indicate baseline levels, whereas red indicates 1-month samples. CRP
indicates C-reactive protein; CV, cardiovascular; GDF-15, growth differentiation factor-15; hs-TnT, high-sensitivity troponin T; MI, myocardial
infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and WBC, white blood cell.
Table 4. Associations Between Continuous (HRs per 50% Increase in Osteoprotegerin) or Quartiles of Osteoprotegerin at Baseline
(n=5135) and 1 Month (n=4233) and Outcome
Model Time
Cardiovascular Death MI Stroke
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
1 Baseline 1.47 (1.31–1.64) <0.0001 1.19 (1.07–1.33) 0.0019 1.21 (0.98–1.50) 0.0773
1 Mo 1.87 (1.48–2.35) <0.0001 1.50 (1.25–1.78) <0.0001 1.76 (1.23–2.51) 0.0019
2 Baseline 1.25 (1.10–1.42) 0.0007 1.11 (0.98–1.25) 0.1054 1.10 (0.86–1.39) 0.4460
1 Mo 1.30 (0.99–1.70) 0.0603 1.22 (1.00–1.50) 0.0517 1.55 (1.02–2.34) 0.0384
3 Baseline 1.05 (0.92–1.22) 0.4604 1.09 (0.95–1.26) 0.2037 1.09 (0.83–1.43) 0.5330
1 Mo 1.05 (0.74–1.50) 0.7886 1.20 (0.94–1.53) 0.1399 1.25 (0.74–2.12) 0.4047
4 Baseline 1.04 (0.90–1.20) 0.6005 1.09 (0.95–1.25) 0.2382 1.08 (0.82–1.41) 0.5947
1 Mo 0.90 (0.63–1.27) 0.5414 1.16 (0.91–1.49) 0.2255 1.22 (0.72–2.08) 0.4567
5 Baseline 0.97 (0.84–1.12) 0.7054 1.04 (0.90–1.20) 0.5700 1.09 (0.83–1.43) 0.5484
1 Mo 0.88 (0.63–1.24) 0.4753 1.14 (0.90–1.46) 0.2835 1.22 (0.72–2.08) 0.4567
6 Baseline 0.90 (0.78–1.05) 0.1853 0.99 (0.86–1.15) 0.9088 1.16 (0.68–1.98) 0.5785
1 Mo 0.89 (0.64–1.25) 0.5092 1.14 (0.89–1.46) 0.2995 1.49 (0.96–2.29) 0.0722
CI indicates confidence interval; HR, hazard ratio; and MI, myocardial infarction. Models are described in the Statistical Analysis section in the Methods.
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was lower in the group randomized to ticagrelor, a survival
bias with ticagrelor may have been present. This is important
because ticagrelor is known to have bleeding as an adverse
effect. Also, the number of bleeding events was not sufficient
for subgroup analysis, evaluating the association between
osteoprotegerin levels and different types of bleeding. Finally,
although we evaluated interactions between osteoprotegerin
levels and outcomes by several subgroups (eg, diabetes
mellitus status and type of ACS), increased osteoprotegerin
levels have been observed in a wide range of diseases and
comorbidities,23,33 also associated with adverse outcome (eg,
aortic stenosis33). Because we were unable to account for
these diseases and comorbidities, we cannot exclude that
they would influence our results. However, our cohort is a
representative population with ACS (ie, no inclusion/exclu-
sion criteria to expect any particular selection).
Conclusion
In patients with ACS treated with dual antiplatelet therapy, we
observed an independent association between osteoprote-
gerin concentrations and the risk of major bleeding both at
baseline and after 1 month. Osteoprotegerin levels were also
associated with ischemic cardiovascular outcomes, even
when adjusting for clinical characteristics and biomarkers of
inflammation and kidney function (but not for cardiac
biomarkers and GDF-15). High osteoprotegerin levels may
be useful in increasing awareness of increased bleeding risk in
patients with ACS receiving antithrombotic therapy.
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University of Hong Kong, HK), Gerald Maurer (Medical University of Vienna, Vienna, AT), Bernhard Meier 
(University Hospital, Bern, CH), João Morais (Santo Andrés Hospital, Leiria, PT), José Nicolau (Heart 
Institute (InCor), São Paulo, BR), Alexander Nikolaevich Parkhomenko (Research Institute of Cardiology, 
Kiew, UA), Ali Oto (Hacettepe Univ School of Medicine, Ankara, TR), Prem Pais (St.John's Medical College, 
Bangalore, IN), Ernesto Paolasso (Estudios Clinicos Latin America, Rosario, AR), Dimitar Raev (Medical 
Institute, Ministry of Interior, Sofia, BG), Dato Seri Robaayah Zambahari (National Heart Institute, Kuala 
Lumpur, MY), Mikhail Ruda (Cardiology Research Center, Moscow, RU), Marc Sabatine (Brigham & 
Women’s Hospital, Boston, MA, US), Anwar Santoso (Udayana School of Medicine, Denpasar, ID), Ki-Bae 
Seung (Kangnam St. Mary's Hospital, Seoul, KR), Lim Soo Teik (Heart Centre, Singapore, SG), Jindrich 
Spinar (University Hospital Brno, Brno, CZ), Piyamitr Sritara (Ramathibodi Hospital, Bangkok, TH), Robert 
Storey (University of Sheffield, Sheffield, UK), Pierre Théroux (Montreal Heart Institute, Montreal, CA), 
Douglas Weaver (Henry Ford Heart & Vascular Inst, Detroit, MI, US), Freek Verheugt (UMC St Radboud, 
Nijmegen, NL), Marius Vintila (St Pantelimon University Hospital, Bucharest, RO), Delon Wu Wu (Chang 
Gung Memorial Hospital-Linkou, Tao-Yuan, TW) 
DSMB members: 
Chairman: Jeffrey L Anderson (Intermountain Medical Center, Murray, UT, US) 
Voting members: David DeMets (University of Wisconsin Medical School, Madison, WI, US), Maarten 
Simoons (Erasmus Medical Centre, Rotterdam, NL), Robert Wilcox (Nottingham University Hospital, 
Nottingham, UK), Frans Van de Werf (University Hospital Leuven, Leuven, BE) 
DSMB statisticians: Susan Anderson (University of Wisconsin Medical School, Madison, WI, US), Erik 
Iverson (University of Wisconsin Medical School, Madison, WI, US) 
ICAC members and operational personnel:  
Co-chairmen: Kenneth W Mahaffey (Duke Clinical Research Institute, Durham, NC, US), Claes Held 
(Uppsala Clinical Research Center, Uppsala, SE) 
Coordinators: Sheila Dickerson (Duke Clinical Research Institute, Durham, NC, US), Matts Högberg 
(Uppsala Clinical Research Center, Uppsala, SE), Debra Montgomery (Duke Clinical Research Institute, 
Durham, NC, US) 
AstraZeneca members: Jan Healy (Wilmington, DE, US), Nardev Khurmi (Wilmington, DE, US), Seva 
Paniflov (Mölndal, SE), Frank Senk (Wilmington, DE, US), LuAnn Vanaman (Wilmington, DE, US),  
Adjudicators: 
North America, India and Australia: John Alexander (Duke University School of Medicine, Durham, NC, 
US), Sana Al-Khatib (Duke University School of Medicine, Durham, NC, US), Jeffrey Berger (Duke 






University School of Medicine, Durham, NC, US), Cheryl Bushnell (Wake Forest University Baptist Medical 
Center, US), Derek Chew (Flinders Medical Center, Australia), Mauricio Cohen (University of North 
Carolina, Chapel Hill, NC, US), Jeffrey Craig (Wake Forest University Baptist Medical Center, Winston-
Salem, NC, US), James De Lemos (Texas Southwestern Medical Center, Dallas, TX, US), John French 
(Liverpool Hospital, Sidney, AU), Robert Giugliano (Brigham and Women´s Hospital, Boston, MA, US), 
Shaun Goodman (St Michaels Hospital, Toronto, CA), Adam Greenbaum (Henry Ford Hospital, Detroit, 
MI, US), Adrian Hernandez, (Duke University School of Medicine, Durham, NC, US), Jason Katz (Duke 
University School of Medicine, Durham, NC, US), Renato Lopes (Duke University School of Medicine, 
Durham, NC, US), Mina Madan (Sunnybrook Health Sciences Centre, Canada), Kenneth Mahaffey (Duke 
University School of Medicine, Durham, NC, US), Peter McCullough (William Beaumont Hospital, Royal 
Oak, MI, US), Darren McGuire (Texas Southwestern Medical Center, Dallas, TX, US), Rajendra Mehta 
(Duke University School of Medicine, Durham, NC, US), Chiara Melloni (Duke University School of 
Medicine, Durham, NC, US), David Morrow (Brigham and Women´s Hospital, Boston, MA, US), Kristen 
Newby (Duke University School of Medicine, Durham, NC, US), Matthew Roe (Duke University School of 
Medicine, Durham, NC, US), Stuart Russell (Johns Hopkins School of Medicine, Baltimore, MD, US), 
Benjamin Scirica (Brigham and Women´s Hospital, Boston, MA, US), Bimal Shah (Duke University School 
of Medicine, Durham, NC, US), Lynda Szczech (Duke University School of Medicine, Durham, NC, US), 
David Whellan (Duke University School of Medicine, Durham, NC, US), David Wiviott (Brigham and 
Women´s Hospital, Boston, MA, US) 
Sweden: Marie Bennermo (Danderyd Hospital, Stockholm, SE), Christina Christersson (Uppsala University 
Hospital, Uppsala, SE), Kai Eggers (Uppsala University Hospital, Uppsala, SE), Bengt-Olof Fredlund 
(Sahlgrenska University Hospital, Gothenburg, SE), Matthias Götberg (Lund University Hospital, Lund, SE), 
Emil Hagström (Uppsala University Hospital, Uppsala, SE), Claes Held (Uppsala University Hospital, 
Uppsala, SE), Ziad Hijazi (Uppsala University Hospital, Uppsala, SE), Mikael Holmgren (Sahlgrenska 
University Hospital, Gothenburg, SE), Stefan James (Uppsala University Hospital, Uppsala, SE), Tomas 
Jernberg (Karolinska University Hospital, Stockholm, SE), Nina Johnston (Uppsala University Hospital, 
Uppsala, SE), Birgitta Jönelid (Uppsala University Hospital, Uppsala, SE), Sasha Koul (Lund University 
Hospital, Lund, SE), Pia Lundman (Danderyd Hospital, Stockholm, SE), Jonas Oldgren (Uppsala University 
Hospital, Uppsala, SE), Katarina Saldeen Nilehn (Sahlgrenska University Hospital, Gothenburg, SE), Ola 
Samuelsson (Sahlgrenska University Hospital, Gothenburg, SE), Karolina Szummer (Karolinska University 
Hospital, Stockholm, SE), Christoph Varenhorst (Uppsala University Hospital, Uppsala, SE), Axel Åkerblom 
(Uppsala University Hospital, Uppsala, SE) 
Statistical centre and involved statisticians: Richard Cairns (Worldwide Clinical Trials, Inc; Nottingham, 
GB), Allan Skene (Worldwide Clinical Trials, Inc; Nottingham, GB), Karen Pieper (Duke Clinical Research 
Institute, Durham, NC, US), Sylvia Olofsson (Uppsala Clinical Research Center, Uppsala, SE), Joseph Ycas 
(AstraZeneca R&D, Wilmington, DE, US) 
Academic coordinating centers and operational personnel: 
Duke Clinical Research Institute (DCRI; Durham, NC, US): Richard Becker, Robert A Harrington 
Uppsala Clinical Research Center (UCR; Uppsala, SE): Inger Ekman, Stefan James, Lars Wallentin 






Central laboratory: Quintiles Central Laboratory, Scotland (Livingston, UK) 
Data coordination: AstraZeneca R&D, Cognizant Technology Solutions, Stockholm, SE (data management 
partner), Medidata Solutions Inc, New York, NY, US (web-based data capture vendor), ICON Clinical 
Research, LP, Philadelphia, PA, US (interactive web/voice response system, vendor)  
All principal investigators by country, PLATO 
Argentina: Pablo Schygiel (Instituto Médico Adrogúe, Adrogué; 6), Oscar Allall (Hospital Córdoba, 
Córdoba; 16), Hugo Ramos (Clínica Privada Caraffa, Córdoba; 12), Julio Bono (Sanatorio Allende, 
Córdoba; 9), Juan Fuselli (CEMIC, Buenos Aires; 4), Carlos Cuneo (Hospital San Bernardo, Salta; 1), Hugo 
Colombo (Clínica Privada Colombo, Córdoba; 6), José Navarro Estrada (Hospital Italiano, Autonomous 
City of Buenos Aires; 7), Carlos Pasinato (Complejo Médico-Policial "Churruca-Visca", Buenos Aires; 3), 
Daniel Nul (PBA - I Medico Constituyentes - Cardiology, Morón; 20), Mario Berli (Hospital Cullen, Santa 
Fé; 37), Rodolfo Milesi (Instituto Cardiovascular Santa Fé, Santa Fé; 38), Miguel Hominal (Sanatorio 
Médico de Diagnóstico y Tratamiento, Santa Fé; 17), Ricardo Fernandez (Sanatorio San Gerónimo, Santa 
Fé; 52), Adrian Hrabar (Sanatorio Modelo de Quilmes, Quilmes; 13), Hector Luciardi (Hospital Centro de 
Salud, Tucuman; 6), Juan Muntaner (Centro Modelo de Cardiologia, Tucuman; 22), Gerardo Zapata 
(Instituto Cardiovascular de Rosario, Rosario; 20), Stella Macin (Instituto de Cardiología de Corriente 
"J.F.Cabral", Corrientes; 24), Marcelo Bettinoti (Sanatorio Güemes, Buenos Aires; 27), Jorge Julio 
Bluguermann (Policlinica Bancaria, Autonomous City of Buenos Aires; 16), Eduardo Gabriel Hasbani 
(Centro Privado de Cardiología, San Miguel de Tucumán; 21), Ruben Piraino (Sanatorio Plaza, Rosario; 
18), Fernando Colombo Berra (Sanatorio de la Trinidad Quilmes, Quilmes; 14), Alejandro Garcia Escudero 
(Clinica Espora, Adrogue; 1) 
Australia: Julian Vaile (Flinders Medical Centre, Bedford Park; 9), Darren Walters (Prince Charles 
Hospital, Chermside; 22), Tony Dart (Alfred Hospital, Melbourne; 4), Chris Hii (Calvary Health Care ACT, 
Melbourne; 12), Paul Garrahy (Princess Alexandra Hospital, Woolloongabba; 21), John Amerena 
(Geelong Hospital, Geelong; 4), John Counsell (Dandenong Hospital, Dandenong; 4), Leonard Arnolda 
(Royal Perth Hospital, Perth; 7) 
Austria: Gerald Maurer (AKH Wien, Wien; 20), Kurt Huber (Wilhelminenspital der Stadt Wien, Wien; 63), 
Franz Roithinger (Thermenklinikum Mödling, Mödling; 5), Josef Hofer (LKH Freistadt, Freistadt; 9), 
Helmut Brussee (Med.-Univ. Graz, Graz; 9), Heinz Krappinger (LKH Villach, Villach; 1), Joachim Nesser (KH 
Elisabethinen Linz, Linz; 3), Peter Siostrzonek (KH der Barmherzigen Schwestern Linz, Linz; 8), Otmar 
Pachinger (Med.-Univ. Innsbruck, Innsbruck; 19), Heinz Drexel (LKH Feldkirch, Feldkirch; 7) 
Belgium: Frank Cools (A.Z. Klina, Brasschaat; 15), Michel Eycken (AZ Sint Augustinus, Wilrijk; 2), Marcelo 
Goldstein (Clinique Sainte-Anne Saint-Remi, Brussels; 14), Patrizio Lancellotti (Centre Hospitalier 
Universitaire Sart Tilman, Liège; 11), Frédéric Mathieu, Pierre Materne (Centre Hospitalier Régional de la 
Citadelle, Liège; 15), Erwin Raymenants (AZ Sint-Maarten, Mechelen; 10), Walter Van Mieghem 
(Ziekenhuis-Oost Limburg Campus Sint-Jan, Genk; 11), Mark Claeys (Universitair Ziekenhuis Antwerpen, 
Edegem; 11), Edouard Benit (Virga Jesse Ziekenhuis, Hasselt; 3), Philippe Dubois (Centre Hospitalier 
Universitaire de charleroi, Charleroi; 5), Dia El Allaf (Centre Hospitalier Hutois, Nuy; 36), Guy Heynickx 






(O.L.V. Ziekenhuis, Aalst; 15), Harry Striekwold (Heilig Hartziekenhuis Mol, Mol; 18), Patrick Timmermans 
(Clinique Saint-Luc, Bouge; 4) 
Brazil: Felipe Lima (HC FMUSP Incor, São Paulo; 63), Leopoldo Piegas (Instituto Dante Pazzanese, São 
Paulo; 6), Paulo Lotufo Hospital (Universitário da Universidade de São Paulo, São Paulo; 17), Valdir Golin 
(Hospital Irmandade Santa Casa de Misericordia de Sao Paulo, São Paulo; 8), Antônio Carvalho 
(Universidade Federal de São Paulo, São Paulo; 11), Lilia Maia (Fundacao da Faculdade Regional de Sao 
Jose do Rio Preto, São José do Rio Preto; 14), Gilmar Greque (Instituto de Moléstias Cardiovasculares, 
São José do Rio Preto; 6), José Francisco Saraiva (Hospital e Maternidade Celso Pierro, Campinas; 16), 
Peo Filho (Hospital Conceição, Porto Alegre; 29), Oscar Dutra (Instituto de Cardiologia do Rio Grande do 
Sul, Porto Alegre; 54), Jorge Ribeiro (Hospital de Clinicas de Porto Alegre, Porto Alegre; 4), Paulo Leaes 
Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; 28), Euler Manenti (Hospital Mãe 
de Deus, Porto Alegre; 4), Jose Antonio Abrantes (Santa Casa de Misericórdia de Pelotas, Porto Alegre; 
34), Paulo Roberto Rossi (Hospital Universitário Evangélico de Curitiba, Curbita; 18), Harry Filho (Inst. 
Cardiologia de Santa Catarina, São José; 10), Denilson Albuquerque (Fundacao Cardio Vascular Pedro 
Ernesto, Rio de Janeiro; 6), Gilmar Reis (Irmandade Santa Casa de Misericordia de Belo Horizonte, Belo 
Horizonte; 60), Álvaro Rabelo (Fundação Baiana de Cardiologia, Salvador; 16), Marcelo Teixeira (Hospital 
Português, Salvador; 2), Délcio Júnior Hospital Universitário da Univ. Federal de Mato Grosso, Campo 
Grande; 33), Maria Fernanda Garcia (Instituto do Coração do Distrito Federal, Brasília; 4), Ludmilla 
Almeida Oliveira (Pro Matre - Instituto do Coração (InCor), Natal; 11), Maria Sanali Paiva (Natal Hospital 
Center, Natal; 11), Yorghos Michalaros (Instituto Previdência Servidores de Minas Gerais, Belo Horizonte; 
40), João Batista Júnior (Hospital Agamenon Magalhães, Recife; 31), Raul Júnior (Hospital Santa Rita, 
Maringá; 32), Hans Fernando Dohmann (Hospital Pró-Cardíaco (PROCEP), Rio de Janeiro; 3), Salvador 
Rassi (Hospital das Clínicas da Universidade Federal de Goiás, Goiânia; 18), Antonio Carlos Sousa 
(Hospital São Lucas, Aracaju; 23), Marco Gomes (Hospital Memorial Arthur Ramos, Maceió; 22), Eduardo 
Maia (Sociedade Espanhola de Beneficencia, Rio de Janeiro; 2), José Neto (Irmandade Santa Casa de 
Misericórdia de Curitiba (PUC-PR), Curitiba; 16), Roberto Botelho (Hospital Santa Catarina, Uberlândia; 
41) 
Bulgaria: 
Dimitar Raev (Central Clinical Hospital, Sofia; 30), Assen Goudev (MHAT Queen Joanna, Sofia; 24), Sotir 
Marchev (5th MHAT, Sofia; 22), Atanas Mihov (MHAT St. Ekaterina, Dimitrovgrad; 20), Anastas Popov 
(MHAT Haskovo, Haskovo; 13), Maria Cekova (MHAT “Georgi Stranski” Cardiology Dept and ICU, Pleven; 
52), Silvia Dimitrova (MHAT Russe, Ruse; 13), Stefan Denchev (MHAT Alexandrovska, Sofia; 30), Mladen 
Grigorov (2nd MHAT, Sofia; 23), Snezhanka Tisheva (MHAT “Georgi Stranski” Cardiology and 
Rheumatology, Pleven; 55), Atanas Penev (MHAT ‘St. Marina’, Varna; 13), Dobri Hazarbasanov (MHAT 
‘St. Anna’, Sofia; 16), Stanislav Petranov (MHAT Burgas, Burgas; 20), Stanislav Petranov (MHAT Plovdiv , 
Plovdiv; 11), Boicho Boichev (MHAT Kazanlak, Kazanlak; 25), Nina Shehova (MHAT Dr.Bratan Shukerov, 
Smolian; 35), Varbitza Hergeldjieva (MHAT Russe, Russe; 10), Toma Vladimirov (MHAT Gabrovo, 
Gabrovo; 2), Fedya Nikolov, Atanas Djurdjev (UMHAT St.Georgi, Plovdiv; 37) 






Canada: Pierre Theroux (Institut de Cardiologie de Montreal, Montréal; 12), James Swan (Scarborough 
Cardiology Research, Scarborough; 64), Barry Rose (The Health Science Centre, St John´s; 9), Christian 
Constance (Hopital Maisonneuve-Rosemont, Montreal; 27), Krishnan Ramanathan (Diamond Health Care 
Centre, Vancouver; 6), Wolf Peter Klinke (Victoria Heart Institute, Victoria; 18), Warren Cantor (Southlake 
Regional Health Centre, Newmarket; 21), Robert Welsh (Edmonton University Hospital, Edmonton; 9), 
John Ducas (St Boniface General Hospital, Winnipeg; 1), Petr Polasek (Kelowna Cardiology Research, 
Kelowna; 2), Thao Huynh Thanh (Hopital General de Montreal, Montreal; 5), Rakesh Bhargava (Lakeridge 
Health Oshawa, Oshava; 16), Robert Teskey (N.B. Heart Centre, Saint John; 20), Saul Vizel (Cambridge 
Memorial Hospital, Cambridge; 23), John Paul Deyoung (Medical Centre Cornwall, Cornwall; 19), Hubert 
Comtois (Cite de la Sante de Laval, Laval; 18), Patrick Ma (Rockyview Hospital, Calgary; 5), Robert Dupuis 
(Centre Hospitalier de la Region de I Amiante, Thetford mines; 10), John Heath (Campbell River Hospital, 
Campbell River; 2), Danielle Dion (Centre Hospitalier Beauce-Etchemin, Saint-Georges; 4), David 
Cleveland (Penticton Regional Hospital, Penticton; 3), Dennis Rupka (Fraser Clinical Trials, New 
Westminster; 10), Shyam Radhakrishnan (Sunnybrook Health Sciences Centre, Toronto; 9), Jayant Bhatt 
Brockville (General Hospital, Brockville; 28), Rodney Zimmermann (Regina General Hospital, Regina; 13), 
Michel Nguyen (C.U.S.E. Site Fleurimont, Sherbrooke; 2), Josep Rodes Cabau (Hopital Laval, Quebec City; 
22), Michel Le May (Ottawa Heart Institute, Ottawa; 8), William Kostuk (London Health Sciences Centre, 
London; 12), Jan Kornder (Surrey Memorial Hospital, Surrey; 3) 
China: Jilin Chen (Fu Wai Hospital, Beijing; 11), Xinchun Yang (Beijing Chaoyang Hospital, Beijing; 61), 
Shuzheng Lv (Anzhen Hospital, Beijing; 22), Yong Huo (Peking University First Hospital, Beijing; 28), 
Jianhua Zhu (Hospital of Zhejiang, Hang Zhou; 19), Zhanquan Li (The Peoples Hospital of Liaoning 
Province, Shenyang; 66), Dejia Huang (Chengdu Hua Xi Hospital, Chengdu; 50), Jiyan Chen (Guang Dong 
Provincial Peoples Hospital, Guangzhou; 41), Ben He (Renji Hospital, Shanghai; 42), Qi Hua (Xuanwu 
Hospital, Beijing; 65), Yaling Han (Shenyang SY P.L.A General Hospital, Shenyang; 13) 
Czech Republic: Jindrich Spinar (Fakultni nemocnice Brno-Bohunice, Brno; 93), Milos Holub (Nemocnice 
Jihlava, Jihlava; 8), Eva Mandysova (Nemocnice Na Homolce, Prague; 11), Jan Belohlavek (Vseobecna 
fakultni nemocnice, Prague; 120), Petr Reichert (Nemocnice Teplice, Teplice; 57), Ondrej Cermak 
(Nemocnice Slany, Slany; 55), Vratislav Dedek (Nemocnice Usti nad Orlici, Usti nad Orlici; 33), Pavel 
Cervinka (Masarykova nemocnice, Usti nad Labern; 50), David Horak, Frantisek Holm (Krajska nemocnice 
Liberec, Liberec; 161), Ladislav Groch (Fakultni nemocnice u Sv. Anny, Brno; 87), Zuzana Motovska 
(Fakultni nemocnice Kralovske Vinohrady, Prague; 145), Rudolf Spacek (Nemocnice na Frantisku, Prague; 
4), Jan Matejka Nemocnice (Pardubice, Pardubice; 45), Leos Pleva, Roman Stipal (Ostrava-Poruba - FN, 
Ostrava-Poruba; 14), Marek Richter (Fakultni nemocnice Olomouc, Olomouc; 17), Jiri Povolny 
(Nemocnice Kladno, Kladno; 7), Jan Vojacek (Fakultni nemocnice Hradec Kralove, Hradec Kralove; 20), Jiri 
Vejvoda (FN Motol, Kardiovaskulární centrum FN Motol, Prague; 55), Zdenek Coufal (Zlin - Krajska nem. 
T.Bati, a.s, Zlin; 12), Zdenek Monhart (Nemocnice Znojmo, Znojmo; 27)  
Denmark: Per Dahl Christensen (Viborg-Kjellerup Sygehus, Viborg; 6), Else Sørensen, Karen Dodt 
(Horsens Sygehus, Horsen; 5), Lars Frost (Regionshospitalet Silkeborg, Silkeborg; 17), Dorthe Dalsgaard 
(Regionshospitalet Herning, Herning; 12), John Markenvard (Fredericia Sygehus, Fredericia; 5), Ole Nyvad 
(Fredericia og Kolding Sygehuse, Kolding; 1), Knud Pedersen (Odense Universitetshospital, Odense; 8), 






Roman Sykulski (Storstrømmens sygehus, Næstved; 26), Kim Klarlund (Køge Sygehus, Køge; 35), Carl 
Dahlstrøm (Sygehus Syd, Slagelse; 14), Thomas Melchior (Roskilde Sygehus, Roskilde; 8), Tomas Jakobsen 
(Hillerød Sygehus, Hillerød; 10), Jan Jensen (Gentofte Amtssygehus, Hellerup; 39), Knud Skagen (Herlev 
Hospital, Herlev; 10), Søren Rasmussen (Hvidovre Hospital, Hvidorvre; 9), Jens Erik Nielsen (Glostrup 
Hospital, Glostrup; 32), Jens Brønnum-Schou (Amager Hospital, Copenhagen; 26), Peer Grande 
(Rigshospitalet, Copenhagen; 55), Christian Tuxen (Frederiksberg Hospital, Frederiksberg; 12), Tonny 
Nielsen (Sydvestjysk sygehus, Esbjerg; 26), Jens Petersen (Sygehus Vendsyssel, Hjørring; 8), Natasha 
Roseva-Nielsen (Sygehus Vestsjælland Holbæk, Holbæk; 13), Allan Mcnair, Margrethe Ege Olsen 
(Frederikssund Sygehus, Frederikssund; 3), Henrik Nielsen (Bispebjerg Hospital, Copenhagen; 2) 
Finland: Ilkka Tierala (HUS, Meilahden sairaala, Helsinki; 6), Antti Ylitalo (Satakunnan keskussairaala, 
Pori; 10), Seppo Utriainen (Etelä-Karjalan keskussairaala, Lappeenranta; 2), Juha Hartikainen (Kuopin 
yliopistollinen sairaalam, Kuopio; 15), Juhani Airaksinen (Turun Yliopistollinen Keskussairaala, Turku; 30), 
Seppo Voutilainen (Päijät-Hämeen keskussairaala, Lahti; 14), Kai Nyman (Keski-Suomen keskussairaala, 
Jyväskylä; 44), Mikko Halkosaari (Keski-Pohjanmaan keskussairaala, Kokkola; 9), Alexandre Hadjikov 
(Lapin keskussairaala, Rovaniemi; 24) 
France: Jean-Pierre Bassand (Hopital Jean Minjoz, Besancon; 18), Jean-Ernst Poulard (Centre Hospitalier 
Général dAbbeville, Abbeville; 10), Nourredine El Mansour (Nouvel Hôpital - Usic, Valenciennes; 73), 
Fabrice Leroy (Centre Hospitalier de Douai, Douai; 11), Gilles Traisnel (Polyclinique du Bois, Lille; 13), Eric 
Decoulx (Hopital de Tourcoing Guy Chatiliez, Tourcoing ; 20), Damien Maes (Clinique du Parc, Croix ; 2), 
Xavier Lamit (Hôpital Intercommunal de Fréjus Saint Raphaël, Fréjus; 2), Eric Maupas (Hôpital Privé les 
Franciscaines, Nîmes; 4), Gilles Bayet (Clinique Rhone Durance, Avignon; 10), Karim Gacem (H Marengo, 
Chloet; 11), Claude Cassat (CHU Dupuytren, Limoges; 4), Pierre Coste (Hôpital Cardiologique du Haut 
Lévêque, Pessaq; 7), Nicolas Delarche (Centre Hospitalier François Mitterrand, Pau; 11), Laurent Ledain 
(Centre Hospitalier St Louis, La Rochelle; 3), Gilles Mougeot (CHG de Senlis, Senlis; 13), Gery 
Hannebicque (Centre Hospitalier d´Arras, Arras; 17), Riadh Rihani (Centre Hospitalier Saint Philibert, 
Lomme; 13), François Philippe (Institut Mutualiste Montsouris, Paris; 4), Jean-Jacques Blanc (Hopital de 
la cavale Blanche, Brest; 15), Bruno Farah (Clinique Pasteur, Toulouse; 17), Hervé Le Breton (Che 
Pontchaillou, Rennes; 3), René Koning (Clinique Saint Hilaire, Rouen; 5), Patrick Henry (Hopital 
Lariboisiere, Paris; 7), Michèle Escande (CH Allauch, Allauch; 5), Jean-Luc Dubois-Rande (Hôpital Henri 
Mondor, Creteil; 7), Simon Elhadad (Centre Hospitalier de Lagny sur Marne, Lagny sur Marne; 48), Gilles 
Grollier (CHU Côte de Nacre, Caen; 9), Yves Cottin (CHU Bocage, Dijon; 15), Philippe Garot (Hôpital 
Claude Galien, Quincy sous Sénart; 10), Olivier Dibon (Hôpital de la Source, Orleans; 16), Jean-François 
Rousseau (CHG Bercagnes, Falaise; 3), Jean Noel Labeque (Centre Hospitalier Cote Basque, Bayonne; 3), 
Patrick Ohlmann (Hôpital de Hautepierre, Strasbourg; 7), Patrick Khanoyan (Hôpital Saint Joseph, 
Marseille; 8) 
Georgia: Vakhtang Chumburidze (National Center of Therapy, Tblisi; 35), Kakhi Paposhvili (Clinical 
Hospital 2, Tblisi; 42), Irakli Megreladze (Cardiology Clinic, Tblisi; 70), Bondo Kobulia (Institute of 
Cardiology, Tblisi; 17), Nodar Emukhvari (Clinic 1, Tblisi; 39), Anzor Melia (Cardiological Clinic "GULI", 
Tblisi; 25), Merab Mamatsashvili (Clinic "ADAPTI", Tblisi; 52), Gulnara Chapidze (Emergency Cardiology 
Centre, Tblisi; 101), George Khabeishvili (Diagnostic Services Clinic, Tblisi; 138) 






Germany: Evangelos Giannitsis (Universitätsklinikum Heidelberg, Heidelberg; 50), Harald Darius 
(Vivantes Netzwerk für Gesundheit GmbH, Berlin; 4), Jürgen Dahl (Kliniken Mariahilf GmbH, 
Mönchengladbach; 39), Norbert Franz (Schüchtermann Klinik, Bad Rothenfelde; 17), Ruth H Strasser 
(Universitätsklinik an der TU Dresden, Dresden; 6), Mathias Borst (Caritas-Krankenhaus Bad 
Mergentheim GmbH, Bad Mergentheim; 9), Karl-Heinz Kuck (Proresearch Klinische Forschung und 
Entwicklung, Hamburg; 6), Hartmut Gülker (Helios Klinikum Wuppertal, Wuppertal; 281), Stephan Lüders 
(St. Josefs-Hospital Cloppenburg, Cloppenburg; 4), Sabine Genth-Zotz (Klinikum der Johannes - 
Gutenberg - Universität, Mainz; 33), Hubertus Heuer (St Johannes Hospital, Dortmund; 158), Michael 
Buerke (Martin-Luther-Universität Halle-Wittenberg, Halle; 7), Andreas Jeron, Christian Hengstenberg 
(Universitätsklinikum Regensburg, Regensburg; 14), Stephan Felix (Klinikum der Ernst-Moritz-Arndt-
Universität Greifswald, Greifswald; 16), Christoph Nienaber (Universitätsklinikum Rostock, Rostock; 9), 
Stavros Konstantinides (Universitätsklinikum der Georg August Universität, Göttingen; 28), Wolfgang 
Schöls (Herzzentrum Duisburg, Duisburg; 32), Markus Lins, Rüdiger Simon (Universitätsklinikum 
Schleswig-Holstein, Kiel; 11), Heribert Schunkert (Universitätsklinikum Schleswig-Holstein, Lübeck; 36), 
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